SandraReynaMD

PubMed

• 11 citations
  Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!
  Amy Bartlett, Stephen J. Kolb, Allison Kingsley, Kathryn J. Swoboda, Sandra P. Reyna
  Contemporary Clinical Trials Communications. 2018-07-20
• 107 citations
  Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
  Deepa H. Chand, Craig M. Zaidman, Kapil Arya, Rachel Millner, Michelle A. Farrar
  The Journal of Pediatrics. 2021-04-01
• 256 citations
  Natural history of infantile-onset spinal muscular atrophy.
  Stephen J. Kolb, Christopher S. Coffey, Jon W. Yankey, Kristin J. Krosschell, W. David Arnold
  Annals of Neurology. 2017-12-01

Journal Articles

• De Novo mutations in ATPA3 cause alternating hemiplegia of Childhood  
  Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, Fontaine B, Walley MN Heavin S, Panagiotakaki E European Alternating Hemiplegia of Chil..., Nat Genet, 1/1/2012
• Observational Study of caloric and nutrient intake, bone density , and body composition in infants and children with Spinal Muscular Atrophy  
  Poruk KE, Davis RH, Smart AL, Chisum BS, LaSalle BA, Chan GM, Gill G, Reyna SP, Swoboda KJ, Neuromuscul Disord, 1/1/2012
• Reliability of the Modified Hammersmith Functional Motor Scale in Young Children with Spinal Muscular Atrophy  
  Krosschell KJ, Scott CB, Maczulski JA, Lewelt AJ, Reyna SP, Swoboda KJ, Muscle Nerve, 1/1/2011
• SMA CARNI-VAL Trial Part II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy  
  Kissel JT, Scott C, Reyna SP, Crawford TO, Simard L, Krosschell K, Acsadi G, Elsheik B, Schroth M, D'Anjou D, LaSalle B, Prior T, Sorenson S, Maczulski J, Bromberg M, ..., PLoS ONE, 1/1/2011
• Compound muscle action potential and motor function in children with spinal muscular atrophy  
  Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D'anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski JA, Stoddard GJ, Elovic E, Swobod..., Muscle Nerve, 1/1/2010
• SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy  
  Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, LaSalle B, Prior TW, Sorenson SL, Maczulski JA, Br..., PLoS ONE, 1/1/2010
• Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome  
  Sweney MT, Silver K, Gerard-Blanluet M, Pedespan JM, Renault F, Arzimanoglou A, Schlesinger- Massart M, Lewelt AJ, Reyna SP, Swoboda KJ, Pediatrics, 1/1/2009
• Phase II open label study of valproic acid in spinal muscular atrophy  
  Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM,..., PLoS ONE, 1/1/2009
• Perspectives on clinical trials in spinal muscular atrophy [Review]  
  Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, Krosschell KJ, Reyna SP, Schroth MK, Scott CB, Simard LR, J Child Neurol, 1/1/2007
• Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease  
  May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL, Horne BD, Kfoury AG, Carlquist JF, Renlund DG, Cardiology, 1/1/2007
• Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?  
  Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappe DL, Muhlestein JB, Cardiology, 1/1/2007
• Sodium channel mutations and susceptibility to heart failure and atrial fibrillation  
  Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer RJ, Anderson JL, JAMA, 1/1/2005
• C-reactive protein predicts death in patients with non-ischemic cardiomyopathy  
  Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Allen Maycock CA, Bair TL, Carlquist JF, Kfoury AG, Anderson JL, Renlund DG, Cardiology, 1/1/2005
• Natural history of denervation in SMA: relation to age, SMN2 copy number, and function  
  Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB, Ann Neurol, 1/1/2005
• Angiotensin converting enzyme inhibition reduces elevated C-reactive protein in patients with angiographic coronary artery disease  
  Allen Maycock CA, Muhlestein JB, Horne BD, Pearson RR, Bair TL, Lim TH, Jones HU, Reyna SP, Moore SV, Renlund DG, Anderson JL, J Am Coll Cardiol, 1/1/2003
• Which lipid/lipoprotein ratio best predicts angiographic coronary artery disease?  
  Bair TL, Muhlestein JB, Carlquist JF, Allen Maycock CA, Pearson RR, Reyna SP, Horne BD, Anderson JL, J Am Coll Cardiol, 1/1/2003
• Which features of the metabolic syndrome predict clinical outcomes (death/myocardial infarction) in patients with angiographic coronary artery disease?  
  Jones HU, Muhlestein JB, Carlquist JF, Horne BD, Pearson RR, Allen Maycock CA, Reyna SP, Bair TL, Lappé DL, Renlund DG, Anderson JL, J Am Coll Cardiol, 1/1/2003
• Low socio-economic status is more predictive of increased hazard in women than men after angiographic diagnosis of coronary artery disease  
  Reyna SP, Muhlestein JB, Horne BD, Bair TL, Allen Maycock CA, Pearson RR, Moore SV, Renlund DG, Anderson JL, J Am Coll Cardiol, 1/1/2003
• Is atrial fibrillation an inflammatory disease, reflected by elevated C-reactive protein?  
  Allen Maycock CA, Lappé DL, Crandall BG, Muhlestein JB, Horne BD, Bair TL, Li Q, Reyna SP, Renlund DG, Anderson JL, J Am Coll Cardiol, 1/1/2003
• Does the -514T gene promoter variant of hepatic lipase predict increased HDL levels and reduced risk of angiographic coronary artery disease?  
  Whiting BM, Anderson JL, King CA, McKinney J, Muhlestein JB, Chaichana K, Bair TL, Reyna SP, Horne BD, Carlquist JF, J Am Coll Cardiol, 1/1/2003
• Do statins provide clinical benefit in high-risk coronary artery disease patients with advanced left ventricular dysfunction?  
  eyna SP, Horne BD, Pearson RR, Bair TL, Allen Maycock CA, Rasmusson KD, Hall J, Moore SV, Anderson JL, Muhlestein JB, Renlund DG, J Am Coll Cardiol, 1/1/2003
• Genetic burden of polymorphisms related to lipid metabolism increases the risk of angiographic coronary artery disease  
  Horne BD, Anderson JL, Muhlestein JB, Renlund DG, Allen Maycock CA, Reyna SP, King CA, Whiting BM, Chaichana K, Carlquist JF, Circulation, 1/1/2002
• Heart failure teaching and monitoring interventions improve measures of clinical practice in the primary care setting  
  Crowell PS, Berg GL, Bateman K, Reyna SP, Allen Maycock CA, Hall J, Rasmusson K, Lappe' JM, Horne BD, Muhlestein JB, Anderson JL, Renlund DG, Circulation, 1/1/2002
• Lower residential economic status and insurance type independently predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary...  
  Horne BD, Muhlestein JB, Renlund DG, Bair TL, Reyna SP, Anderson JL, Circulation, 1/1/2002
• Elevated C-reactive protein predicts death in patients with left ventricular dysfunction in the absence of ischemic heart disease  
  Reyna SP, Muhlestein JB, Moore SV, Allen Maycock CA, Horne BD, Pearson RR, Walker KM, Hall J, Lappe' DL, Lombardi WL, Renlund DG, Circulation, 1/1/2001
• Join now to see all